drugset / Trial / NCT01025297
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the standard bi-therapy alone.
Timeline
- Start
- 2008-07
- Primary completion
- 2012-12
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interleukin-7 | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 20 ug/kg | Subcutaneous |